MiraLAX® has a triple mechanism of action that hydrates, softens, and gently relieves1-3

The triple action of MiraLAX®

The triple action of MiraLAX® provides proven results and a comfortable patient experience

MiraLAX® triggers peristalsis without interacting with bacteria6 or causing nerve stimulation,2 which can lead to harsh side effects.

  • Doesn’t metabolize in the intestine, which could cause bloating and gas buildup as with fibers such as Metamucil®6,7
  • Encourages gentle peristalsis, unlike stool softeners such as Colace®, which do not prompt peristalsis and could cause cramps and diarrhea7
  • Doesn’t forcefully stimulate colonic nerves, which could cause stomach discomfort and cramps, as with stimulant laxatives such as Dulcolax®7

The trademarks mentioned herein are owned by their respective owners.

See how MiraLAX® works in the body

MiraLAX® : Its triple mechanism of action relieves constipation without causing bloating, cramping, gas, or urgency4-6

In multiple clinical trials, MiraLAX® has been proven to

MiraLAX® is the ONLY OTC osmotic laxative with a prescription heritage and is favored by both physicians and patients10,11

MiraLAX® is supported by 22 years of safe and effective use. It was FDA approved in 1999 as a Rx, and as an OTC product in 200612,13

MiraLAX® provides predictable and reliable relief for a broad range of patients

MiraLAX® is available in a variety of dosing sizes, including travel-size packets

MiraLAX® is easily accessible at national drug store chains, mass merchandisers, online retailers, and club stores

Start your patients on triple-action MiraLAX®

Free Samples and Coupons

Click to expand.

    References: 1. Schiller LR, Emmett M, Santa Ana CA, Fordtran JS. Osmotic effects of polyethylene glycol. Gastroenterology. 1988;94(4):933-941. doi:10.1016/0016-5085(88)90550-1 2. Hammer HF, Santa Ana CA, Schiller LR, Fordtran JS. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest. 1989;84(4):1056-1062. doi:10.1172/JCI114267 3. Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol. 2011;25(Suppl B):16B-21B. 4. DiPalma JA, DeRidder PH, Orlando RC, et al. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol. 2000;95(2):446-450. doi:10.1111/j.1572-0241.2000.01765.x 5. DiPalma JA, Cleveland MB, McGowan J, Herrera JL. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J. 2007;100(11):1085-1090. doi:10.1097/SMJ.0b013e318157ec8f 6. Alper A, Pashankar DS. Polyethylene glycol: a game-changer laxative for children. J Pediatr Gastroenterol Nutr. 2013;57(2):134-140. doi:10.1097/MPG.0b013e318296404a 7. Fiorini K, Sato S, Schlachta CM, Alkhamesi NA. A comparative review of common laxatives in the treatment of constipation. Minerva Chir. 2017;72(3):265-273. doi:10.23736/S0026-4733.17.07236-4 8. MiraLAX® Drug Facts. 9. Cleveland MvB, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J. 2001;94(5):478-481. 10. Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144(1):211-217. doi:10.1053/j.gastro.2012.10.029 11. Data on file. Bayer Pharmaceuticals. 12. US Food and Drug Administration. NDA 20-698. Approval letter for MiraLAX powder. February 18, 1999. 13. US Food and Drug Administration. NDA 22-015. Approval letter for MiraLAX powder OTC. October 6, 2006. 14. U.S. News & World Report and Pharmacy Times. Nonfiber Laxatives Rankings. Accessed September 9, 2021. https://health.usnews.com/drugs/rankings/top-rec-nonfiber-laxatives 15. DiPalma JA, Cleveland MvB, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436-1441. doi:10.1111/j.1572-0241.2007.01199.x